Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Virol J ; 21(1): 130, 2024 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-38840177

RESUMO

BACKGROUND: Limited data is available regarding the severity and mortality of Mpox in individuals with immunocompromised conditions. Therefore, we performed this meta-analysis to understand the impact of HIV- or non-HIV-associated immunosuppression on the severity of Mpox requiring hospitalization and mortality. METHODS: A thorough literature search was performed from 2022 up to January 2024. The results were presented as odds ratios (ORs). We only included patients who required hospitalization for severity rather than isolation. RESULTS: A total of 34 studies were included in this analysis. Our analysis did not find a significant difference in the hospitalization risk between HIV-positive individuals and those who were HIV-negative (OR = 1.03; P = 0.85; 7 studies; CD4 count of fewer than 200 cells/µL was less than 0.5% across all studies). Patients with a CD4 count lower than 200 cells/µL or an unsuppressed RNA viral load (> 200 copies/ml) had a significantly higher hospitalization risk (OR = 5.3, P < 0.001) and (OR = 3, P < 0.001), respectively. Most of the reported deaths were reported in patients with HIV with CD4 counts below 200 cells/µL, with some fatal cases occurring in non-HIV immunosuppressed patients, particularly organ transplant recipients. Based on the autopsy findings, Mpox was confirmed in multiple organs, particularly the digestive tract, lung, and testes. Furthermore, some studies documented cases of death that were suspected to be related to hemophagocytic lymphohistiocytosis (HLH) and immune reconstitution inflammatory syndrome (IRIS). Most of the death reports showed concomitant non-Mpox infections at the time of hospitalization and death CONCLUSIONS: Our finding shows that Mpox acts as an opportunistic pathogen in immunocompromised individuals. These individuals should be prioritized for early care and closely monitored for signs of deteriorating clinical conditions. Clinical manifestations and autopsy findings strongly suggest Mpox dissemination to multiple organs, particularly the digestive tract, and lungs. However, the presence of concomitant non-Mpox infections complicates the assessment of the attribution of Mpox to death. Caution should be exercised when interpreting data suggesting poorer outcomes in individuals with non-HIV immunosuppression, as current evidence is scarce and further research is needed.


Assuntos
Infecções por HIV , Hospitalização , Hospedeiro Imunocomprometido , Mpox , Humanos , Hospitalização/estatística & dados numéricos , Infecções por HIV/mortalidade , Infecções por HIV/complicações , Infecções por HIV/imunologia , Contagem de Linfócito CD4 , Mpox/epidemiologia , Mpox/mortalidade , Surtos de Doenças , Terapia de Imunossupressão/efeitos adversos , Carga Viral
2.
Langenbecks Arch Surg ; 409(1): 204, 2024 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-38963576

RESUMO

PURPOSE: Our study aimed to compare the effectiveness and complications of the transoral endoscopic thyroidectomy submental vestibular approach (TOETSMVA) versus the transoral endoscopic thyroidectomy vestibular approach (TOETVA) or conventional open thyroidectomy (COT) in patients with early-stage papillary thyroid carcinoma (PTC). METHODS: We searched online databases up to January 2024. The outcomes were analyzed using RevMan 5.4 and inverse variance. RESULTS: Seven studies (two RCTs and five retrospective cohort studies) were included. We established higher significance differences for TOETSMVA in comparison with TOETVA in terms of all primary outcomes; operation time, hospital stay, number of resected lymph nodes [MD -21.05, 95% CI= -30.98, -11.12; p < 0.0001], [MD -1.76, 95% CI= -2.21, -1.32, p < 0.00001], [MD -2.99, 95% CI= -19.75, 13.76, p < 0.73], [MD -0.83, 95% CI = -1.19 to -0.47; p < 0.00001], respectively, except the drainage volume, it showed no difference [MD -2.99, 95% CI= -19.75, 13.76, p < 0.73]. In secondary outcomes, it was favored only in mandibular numbness and return to normal diet outcomes. Additionally, TOETSMVA compared with COT showed a significant difference in drainage volume, pain, cosmetic effect, and satisfaction score. CONCLUSIONS: TOETSMVA showed a significant improvement compared to the TOETVA in operation time, hospital stay, number of resected lymph nodes, mandibular numbness, and return to normal diet but did not show a difference in drainage volume. However, TOETSMVA was better in cosmetic effect, drainage volume, satisfaction, and pain scores compared with COT. Further RCTs with larger sample size, multicentral, and longer follow-up are necessary to evaluate the limitations.


Assuntos
Cirurgia Endoscópica por Orifício Natural , Câncer Papilífero da Tireoide , Neoplasias da Glândula Tireoide , Tireoidectomia , Humanos , Tireoidectomia/métodos , Câncer Papilífero da Tireoide/cirurgia , Câncer Papilífero da Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgia , Neoplasias da Glândula Tireoide/patologia , Cirurgia Endoscópica por Orifício Natural/métodos , Estadiamento de Neoplasias , Duração da Cirurgia , Resultado do Tratamento
3.
CNS Spectr ; 27(5): 639-644, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-34121653

RESUMO

BACKGROUND: Altered peripheral immune/inflammatory system and brain volumetric changes have been implicated in the pathophysiology of bipolar disorder (BD). This study aimed to evaluate how peripheral levels of cytokines are related to volumetric brain changes in euthymic patients with BD. METHODS: Euthymic patients with BD (n = 21) and healthy controls (n = 22) were enrolled in this exploratory study. Blood samples were collected on the same day of clinical assessment and neuroimaging. Cytokines were measured through cytometric bead array method. Neuroimaging data were acquired using a sagittal three-dimensional magnetic resonance imaging T1-weighted fast field echo sequence and was processed using FreeSurfer. RESULTS: Compared to controls, BD patients had significantly lower volumes in the cingulate, medial-orbitofrontal (MOF) and parahippocampal regions. We found a negative correlation between right MOF volume and interferon-gamma levels (ß = -0.431, P = .049) and a positive correlation between interleukin-10 levels and left posterior cingulate volume (ß = 0.457, P = .048). CONCLUSION: Our results support the involvement of inflammatory pathways in structural brain changes in BD.


Assuntos
Transtorno Bipolar , Humanos , Substância Cinzenta/patologia , Interleucina-10 , Mediadores da Inflamação , Interferon gama , Imageamento por Ressonância Magnética/métodos , Encéfalo
4.
Neurol Sci ; 41(8): 2201-2206, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32172403

RESUMO

BACKGROUND: Sexual dysfunction (SD) is a common, yet under-reported, non-motor symptom (NMS) of Parkinson's disease (PD). The present study investigated the sexual functions in PD male patients, its correlation with motor and other NMSs, and their impact on health-related quality of life (HRQoL). METHODS: The sexual functions of 40 PD male patients were assessed using the International Index of Erectile Function (IIEF) and compared to 25 healthy age-matched controls. Patients were evaluated using the NMS Scale (NMSS) and the Arabic version of the Parkinson's-Disease Questionnaire (PDQ-39). We compared the sexual functions of younger (≤ 55 years) and elder (> 55 years) males and tested the correlations between sexual functions and motor, other NMSs, and HRQoL. RESULTS: Seventy percent of PD male patients reported erectile dysfunction. They showed significantly worse total (p < 0.001) and subscores of IIEF, compared to healthy controls. The total IIEF was inversely correlated to age of patients (p = 0.013), age at onset (p = 0.043), total, cognitive/mood, gastrointestinal and urinary domains of NMSS, and the cognitive domain of PDQ-39 (p = 0.013). Age was the main predictor (ß = - 0.581, p = 0.006) of SD. Elder patients showed worse sexual functions, stronger correlations to other NMSs, and more impact on HRQoL than younger patients. CONCLUSION: Sexual functions are worse among PD male patients with age as the main predictor. SD was associated with worse cognitive/mood and urinary domains of NMSS and has a negative impact on the patients' HRQoL among elder males.


Assuntos
Doença de Parkinson , Disfunções Sexuais Fisiológicas , Idade de Início , Idoso , Humanos , Masculino , Doença de Parkinson/complicações , Doença de Parkinson/epidemiologia , Qualidade de Vida , Disfunções Sexuais Fisiológicas/epidemiologia , Disfunções Sexuais Fisiológicas/etiologia , Inquéritos e Questionários
5.
Adv Exp Med Biol ; 1079: 93-102, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29767290

RESUMO

To date, there is no definitive treatment for Alzheimer's disease (AD). The realm of stem cells is very promising in regenerative medicine, particularly for neurodegenerative diseases. Various types of stem cells have been used in preclinical/clinical trials for AD aiming the development of an elusive disease modifying therapy. Over the last decade, much knowledge has been gained in this field regarding types of cells, routes and timing of administration, and outcomes of stem cells-based strategies for AD. In this chapter, we will trace the state of art and the challenges facing the use of stem cells in AD.


Assuntos
Doença de Alzheimer/terapia , Medicina Regenerativa , Células-Tronco/citologia , Humanos
6.
Eur Child Adolesc Psychiatry ; 27(3): 267-277, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28905127

RESUMO

An association between primary headaches and attention-deficit/hyperactivity disorder (ADHD) has long been suggested. Moreover, headache is regarded as a common side effect of stimulants, the most effective treatment for ADHD. So far, no systematic review has evaluated the potential association between ADHD and headache. We performed a systematic review of the literature and a meta-analysis of all reported studies on ADHD and primary headaches. Our analysis showed a positive association between ADHD and migraine (OR 1.322, 95% CI 1.018-1717, p value 0.036), but not with tension-type headache. There is a significant association between migraine and ADHD. The mechanisms underlying this association remain to be elucidated, warranting further studies.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/etiologia , Transtornos de Enxaqueca/complicações , Adolescente , Criança , Pré-Escolar , Humanos
7.
J Mov Disord ; 2024 Jun 25.
Artigo em Inglês | MEDLINE | ID: mdl-38915261

RESUMO

Objective: Pain is one of the most common non-motor symptoms in Parkinson's disease (PD), with variable characteristics among populations. This multicenter Egyptian study aimed to translate and validate the King's Parkinson's Disease Pain Scale (KPPS) and questionnaire (KPPQ) into Arabic versions and to investigate the pain characteristics in Egyptian people with PD (PWP). Methods: 192 PWP and 100 sex and age-matched controls were evaluated by KPPS-Arabic and KPPQ-Arabic. Both tools were assessed for test-retest reliability, floor or ceiling effects, construct validity and convert validity. PWP were assessed also by MDS-UPDRS, Hoehn and Yahr, NMSS, PD Questionnaire-39, and the Non-Motor Fluctuation Assessment (NoMoFA). Results: KPPS-Arabic and KPPQ-Arabic showed inter and intra-rater consistency and high validity, with an acceptable ceiling effect. 188 PWP (97.9%) reported at least 1 type of pain, (p<0.001). The severity and prevalence of KPPS-Arabic domains were significantly higher in all pain domains among PWP compared to controls (p < 0.001). Fluctuation-related and musculoskeletal pains were the most common (81.3% and 80.7%, respectively). In the PD group, the total and domains of KPPS-Arabic were significantly correlated to the MDS-UPDRS total, parts I, II, III, PIGD, axial, and H &Y scores, but not age or age of onset. Predictors of KPPS-Arabic included the total MDS-UPDRS, part III-Off, disease duration, total NMSS, and NoMoFA. Conclusion: The current multicentre study provided a validated Arabic versions of KPPS and KPPQ, with high reliability and validity, and demonstrated a high prevalence and severity of pain within Egyptian PWP and characterized its determinants.

8.
Stroke ; 44(2): 538-41, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23212167

RESUMO

BACKGROUND AND PURPOSE: Intracranial arterial steno-occlusive disease is prevalent among non-white populations. We explored whether a similar pattern exists in Egyptians and assessed its clinical-radiological associations. METHODS: Consecutive acute ischemic stroke patients were recruited for 6 months and had magnetic resonance imaging/magnetic resonance angiography of brain within 2 days of the event. Magnetic resonance angiography was analyzed for significant stenosis (>50%), flow gaps, and complete occlusions in the major intracranial arteries. RESULTS: A total of 143 patients completed the study (62.4 ± 12.6 years, 58.7% males). Magnetic resonance angiography showed symptomatic arterial stenosis in 27.3%, asymptomatic stenosis in 16.1%, and occlusions in 23.7% patients. Carotid duplex showed stenosis >70% in only 7.7% patients. Patients with intracranial arterial steno-occlusive disease had higher National Institutes of Health Stroke Score at admission (10.9 ± 7 versus 8 ± 5.6; P=0.01). CONCLUSIONS: Symptomatic and asymptomatic intracranial arterial steno-occlusive disease was prevalent in this Egyptian acute stroke sample. This might have important implications on stroke management in this population.


Assuntos
Isquemia Encefálica/epidemiologia , Estenose das Carótidas/epidemiologia , Doenças Arteriais Intracranianas/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Idoso , Arteriopatias Oclusivas/diagnóstico , Arteriopatias Oclusivas/epidemiologia , Isquemia Encefálica/diagnóstico , Estenose das Carótidas/diagnóstico , Egito/epidemiologia , Feminino , Humanos , Doenças Arteriais Intracranianas/diagnóstico , Masculino , Pessoa de Meia-Idade , Acidente Vascular Cerebral/diagnóstico
9.
J Alzheimers Dis ; 92(1): 129-139, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36710674

RESUMO

BACKGROUND: Apathy is among the neuropsychiatric symptoms frequently observed in people with cognitive impairment. It has been postulated to be a potential predictor of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). OBJECTIVE: To detect conversion rates from MCI to AD, and to determine the effect of apathy on the progression to AD in patients with MCI enrolled in the Texas Alzheimer's Research and Care Consortium (TARCC) cohort. METHODS: Apathy was determined by a positive response to the respective item in the Neuropsychiatric Inventory -Questionnaire (NPI-Q) completed by family members or caregivers. The final dataset included 2,897 observations from 1,092 individuals with MCI at the baseline. Kaplan-Meier survival curves were estimated to provide indices of the probability of conversion to AD over time across all individuals as well as between those with and without apathy. Cox proportional hazards regression measured the hazard associated with apathy and several other predictors of interest. RESULTS: Over a period of 8.21 years, 17.3% of individuals had conversion from MCI to AD (n = 190 of 1,092 total individuals) across observations. The median time-to-conversion across all participants was 6.41 years. Comparing individuals with apathy (n = 158) versus without apathy (n = 934), 36.1% and 14.2% had conversion to AD, respectively. The median time-to-conversion was 3.79 years for individuals with apathy and 6.83 years for individuals without apathy. Cox proportional hazards regression found significant effects of several predictors, including apathy, on time-to-conversion. Age and cognitive performance were found to moderate the relationship between apathy and time-to-conversion. CONCLUSIONS: Apathy is associated with progression from MCI to AD, suggesting that it might improve risk prediction and aid targeted intervention delivery.


Assuntos
Doença de Alzheimer , Apatia , Disfunção Cognitiva , Humanos , Doença de Alzheimer/psicologia , Apatia/fisiologia , Texas , Testes Neuropsicológicos , Disfunção Cognitiva/psicologia , Progressão da Doença
10.
Acta Neurol Belg ; 123(5): 1725-1733, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35854172

RESUMO

INTRODUCTION: White matter hyperintensities (WMHs) are frequently found in migraineurs. However, their clinical significance and correlation to different migraine phenotypes and treatment responses are not well defined. The study aimed to examine the association of WMHs with migraine clinical patterns and treatment response. AIM OF WORK: We aimed to evaluate the association between WMHs and migraine phenotypes and explore the relationship of WMHs to treatment response. METHODS: Our cross-sectional study formed of 500 migraineurs who sought treatment in Kafr el-sheik university hospital and underwent (3 T) MRI to evaluate WMHs. Different migraine phenotypes were compared between patients with and without WMHs. According to reduced headache pain intensity and frequency, these patients were divided into treatment responder and non-responder groups. RESULTS: A total of 145 patients (29%) had WMHs. Patients with WMHs were significantly older, had a longer disease duration, and higher attack frequency. Patients who did not respond to acute and maintenance medications had a higher frequency of WMHs and high WMHs Scheltens score. Migraine with Aura and the presence of vomiting and dizziness were predictors for the development of WMHs. CONCLUSION: WMHs are more common in migraine with aura. It is more frequent in migraine associated with vomiting and dizziness. WMHs increased with advancing age and more severe disease burden. Poorer response to acute and prophylactic medications was found in patients with WMHs.


Assuntos
Epilepsia , Leucoaraiose , Transtornos de Enxaqueca , Enxaqueca com Aura , Substância Branca , Humanos , Substância Branca/diagnóstico por imagem , Tontura , Estudos Transversais , Transtornos de Enxaqueca/diagnóstico por imagem , Imageamento por Ressonância Magnética , Vertigem
11.
J Affect Disord ; 324: 286-293, 2023 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-36584711

RESUMO

BACKGROUND: Artificial intelligence is currently being used to facilitate early disease detection, better understand disease progression, optimize medication/treatment dosages, and uncover promising novel treatments and potential outcomes. METHODS: Utilizing the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) dataset, we built a machine learning model to predict depression remission rates using same clinical data as features for each of the first three antidepressant treatment steps in STAR*D. We only used early treatment data (baseline and first follow up) in each STAR*D step to temporally analyze predictive features of remission at the end of the step. RESULTS: Our model showed significant prediction performance across the three treatment steps, At step 1, Model accuracy was 66 %; sensitivity-65 %, specificity-67 %, positive predictive value (PPV)-65.5 %, and negative predictive value (NPV)-66.6 %. At step 2, model accuracy was 71.3 %, sensitivity-74.3 %, specificity-69 %, PPV-64.5 %, and NPV-77.9 %. At step 3, accuracy reached 84.6 %; sensitivity-69 %, specificity-88.8 %, PPV-67 %, and NPV-91.1 %. Across all three steps, the early Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) scores were key elements in predicting the final treatment outcome. The model also identified key sociodemographic factors that predicted treatment remission at different steps. LIMITATIONS: The retrospective design, lack of replication in an independent dataset, and the use of "a complete case analysis" model in our analysis. CONCLUSIONS: This proof-of-concept study showed that using early treatment data, multi-step temporal prediction of depressive symptom remission results in clinically useful accuracy rates. Whether these predictive models are generalizable deserves further study.


Assuntos
Transtorno Depressivo Maior , Humanos , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/tratamento farmacológico , Inteligência Artificial , Estudos Retrospectivos , Antidepressivos/uso terapêutico , Resultado do Tratamento , Aprendizado de Máquina , Citalopram/uso terapêutico
12.
J Alzheimers Dis ; 86(1): 403-411, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35068461

RESUMO

BACKGROUND: Apathy is among the most frequent neuropsychiatric syndromes in Alzheimer's disease (AD). OBJECTIVE: To determine the prevalence of apathy and the associated clinical and laboratorial parameters (focus on inflammatory biomarkers) in patients with dementia enrolled at the Texas Alzheimer's Research and Care Consortium (TARCC) study. METHODS: This is a cross-sectional analysis of TARCC baseline. Participants were evaluated through different clinical tools, including the Mini-Mental State Examination (MMSE) and the Lawton-Brody Instrumental Activities of Daily Life (IADL)/Physical Self-Maintenance Scale (PSMS). Apathy was defined by a positive response to the respective item in the Neuropsychiatric Inventory-Questionnaire applied to caregivers. Serum levels of 16 biomarkers were determined by HumanMap multiplex immunoassay. Comparisons between apathy versus non-apathy groups were carried out with non-parametric tests. Logistic regression and the least absolute shrinkage and selection operator (LASSO) were used to separately model apathy as a function of each biomarker, adjusted for the potential confounders. RESULTS: From 1,319 patients with AD (M/F: 579/740, mean age ±â€ŠSD: 75.3 ±â€Š8.4), 373 (28.3%) exhibited apathy. When categorized according to the presence of apathy, the groups had significant differences in sex, diabetes diagnosis, and tobacco use. The apathy group also had worse cognitive performance and daily functioning than the non-apathy group as assessed, respectively, by MMSE and IADL/PSMS. Higher levels of interleukin-6, interleukin-10, and leptin were associated with higher odds of apathy. CONCLUSION: Apathy is associated with cognitive and functional status in AD. The association between apathy and peripheral inflammatory mediators deserves further investigation.


Assuntos
Doença de Alzheimer , Apatia , Doença de Alzheimer/psicologia , Estudos Transversais , Humanos , Testes Neuropsicológicos , Texas/epidemiologia
13.
Agri ; 32(4): 238-239, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33398863

RESUMO

OBJECTIVE: Vertebral compression fractures due to osteoporosis are seen frequently. Osteoporotic compression fractures can cause severe pain, limitation of physical activities and impairment of quality of life. Kyphoplasty, a minimally invasive procedure, could be effective in many cases and can provide fast pain relief. CASE: A patient with a history of falling from a height of 8 months duration visited our pain clinic. Opioids and anti-inflammatory analgesics were administered together with physical therapy and facet joint injections with no improvement. Radiological examination of the patient showed collapse fracture of L2 and L4 vertebrae on top of severe osteoporosis. Kyphoplasty was performed at the level of L2 vertebrae followed by 50% relieve in her pain (VAS score reduction from 8 to 3) and hence she was capable to resume her daily activities. CONCLUSION: Percutaneous balloon kyphoplasty is a safe and effective procedure for the treatment of elder patient with osteoporotic vertebral compression fractures.


Assuntos
Fraturas por Osteoporose/diagnóstico , Fraturas da Coluna Vertebral/diagnóstico , Idoso , Diagnóstico Diferencial , Feminino , Humanos , Cifoplastia , Vértebras Lombares , Osteoporose Pós-Menopausa , Fraturas por Osteoporose/diagnóstico por imagem , Fraturas por Osteoporose/cirurgia , Medição da Dor , Fraturas da Coluna Vertebral/diagnóstico por imagem , Fraturas da Coluna Vertebral/cirurgia
14.
J Psychiatr Pract ; 25(4): 279-289, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31291208

RESUMO

BACKGROUND: Earlier research indicated that nearly 20% of patients diagnosed with either bipolar disorder (BD) or borderline personality disorder (BPD) also met criteria for the other diagnosis. Yet limited data are available concerning the potential impact of co-occurring BPD and/or BPD features on the course or outcome in patients with BD. Therefore, this study examined this comorbidity utilizing the standardized Borderline Personality Questionnaire (BPQ). METHODS: This study involved 714 adult patients with a primary diagnosis of BD per DSM-IV criteria who were admitted to the psychiatric unit at an academic hospital in Houston, TX between July 2013 and July 2018. All patients completed the BPQ within 72 hours of admission. Statistical analysis was used to detect correlations between severity of BD, length of stay (LOS), and scores on the BPQ. A machine learning model was constructed to predict the parameters affecting patients' readmission rates within 30 days. RESULTS: Analysis revealed that the severity of certain BPD traits at baseline was associated with mood state and outcome measured by LOS. Inpatients with BD who were admitted during acute depressive episodes had significantly higher mean scores on 7 of the 9 BPQ subscales (P<0.05) compared with those admitted during acute manic episodes. Inpatients with BD with greater BPQ scores on 4 of the 9 BPQ subscales had significantly shorter LOS than those with lower BPQ scores (P<0.05). The machine learning model identified 6 variables as predictors for likelihood of 30-day readmission with a high sensitivity (83%), specificity (77%), and area under the receiver operating characteristic curve of 86%. CONCLUSIONS: Although preliminary, these results suggest that inpatients with BD who have higher levels of BPD features were more likely to have depressive rather than manic symptoms, fewer psychotic symptoms, and a shorter LOS. Moreover, machine learning models may be particularly valuable in identifying patients with BD who are at the highest risk for adverse consequences including rapid readmission.


Assuntos
Transtorno Bipolar/psicologia , Transtorno da Personalidade Borderline/psicologia , Aprendizado de Máquina , Readmissão do Paciente , Adulto , Afeto , Transtorno Bipolar/terapia , Feminino , Humanos , Pacientes Internados , Tempo de Internação , Masculino , Modelos Estatísticos , Readmissão do Paciente/estatística & dados numéricos , Personalidade
15.
Dement Neuropsychol ; 12(2): 143-151, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29988333

RESUMO

A growing body of evidence indicates that systemic lupus erythematosus (SLE) is associated with increased risk of cognitive impairment and dementia. However, to date, no studies have been conducted to quantitatively summarize and evaluate the consistency of data. OBJECTIVE: To quantitatively evaluate the relationship of SLE and antiphospholipid antibodies (aPL) with cognitive dysfunction and dementia. METHODS: All relevant literature was retrieved from Pubmed, Scopus, and PsycINFO databases. The meta-analysis was performed using effect estimates and 95% confidence intervals (CIs) to calculate pooled risk estimates. The heterogeneity among studies was also examined. RESULTS: The meta-analysis included 11 original studies involving a total of 81,668 patients with dementia and 407 patients with cognitive dysfunction. There were significant associations on fixed-effect models between SLE and dementia (3 studies; RR=1.50; 95% CI=1.37-1.64), SLE and cognitive dysfunction (4 studies; OR=2.97; 95% CI=1.72-5.15), and aPL and cognitive dysfunction (5 studies, OR=1.97; 95% CI=1.55-2.52). We also combined cognitive dysfunction and dementia outcomes as they both represented cognitive impairment. There were significant associations between aPL and cognitive impairment (6 studies; OR=2.03; 95% CI=1.62-2.55), and SLE and cognitive impairment (7 studies; OR=1.83; 95% CI=1.42-2.35). Moderate heterogeneity (I2=45.7%) was found in the association between SLE and cognitive impairment, low heterogeneity (I2=21.8%) in the association between SLE and dementia, and near zero heterogeneity for the other three main analyses. CONCLUSION: Both SLE and aPL are associated with cognitive impairment.


Um volume crescente de evidências indica que o lúpus eritematoso sistêmico (LES) está associado ao aumento do risco de comprometimento cognitivo e demência. No entanto, até o presente momento nenhum estudo foi conduzido a fim de resumir e avaliar quantitativamente a consistência dos dados. OBJETIVO: Avaliar quantitativamente a relação entre o LES e anticorpos anticorpos antifosfolípides (aPL) com disfunção cognitiva e demência. MÉTODOS: Toda literatura relevante foi recuperada das bases de dados Pubmed, Scopus e PsycINFO. A meta-análise foi realizada utilizando as estimativas de efeito e os intervalos de confiança de 95% (ICs) para calcular as estimativas de risco combinadas. A heterogeneidade entre os estudos também foi examinada. RESULTADOS: A meta-análise incluiu 11 estudos originais com um total de 81.668 pacientes com demência e 407 pacientes com disfunção cognitiva. Houve associações significativas (modelos de efeitos fixos) entre LES e demência (3 estudos, RR=1,50; IC 95%=1,37-1,64), LES e disfunção cognitiva (4 estudos; OR=2,97; IC 95%=1,72-5,15), e aPL e disfunção cognitiva (5 estudos, OR=1,97; IC 95%=1,55-2,52). Além disso, combinamos os resultados da disfunção cognitiva e demência, uma vez que ambos representaram déficit cognitivo. Houve associações significativas entre aPL e comprometimento cognitivo (6 estudos, OR=2,03, IC 95%=1,62-2,55), e LES e comprometimento cognitivo (7 estudos, OR=1,83; IC 95%=1,42-2,35). Uma heterogeneidade moderada (I2=45,7%) foi encontrada na associação entre LES e comprometimento cognitivo, heterogeneidade baixa (I2=21,8%) na associação entre LES e demência e heterogeneidade quase zero para as outras três principais análises. CONCLUSÃO: Tanto o LES como aPL estão associados a déficit cognitivo.

16.
Neurosci Biobehav Rev ; 92: 477-485, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29940237

RESUMO

Activation of the kynurenine pathway is one of the described mechanisms by which inflammation can induce depression. It involves multiple pathways including interference with the bioavailability of tryptophan central to the synthesis of the neurotransmitter serotonin. In this systematic review, we examine the relationship between kynurenine metabolites (kynurenine, kynurenic acid, tryptophan, quinolinic acid, the ratio of kynurenine and tryptophan) and mood disorders by conducting a meta-analysis. Fifty-six studies were identified, 21 met inclusion criteria and 14 were deemed suitable (9 investigating unipolar depression and 5 bipolar disorder). We found decreased levels of kynurenine in unipolar major depression vs. healthy controls but studies were significantly heterogeneous in nature. No significant differences were found in tryptophan levels or kynurenine/tryptophan ratios. Kynurenine metabolites are likely to play a role in major depression but an exact etiological role in mood disorder seem complex and requires further research.


Assuntos
Cinurenina/metabolismo , Transtornos do Humor/metabolismo , Transdução de Sinais/fisiologia , Humanos , Ácido Cinurênico , Ácido Quinolínico/metabolismo , Serotonina/metabolismo , Triptofano/metabolismo
17.
Pain Physician ; 21(5): E501-E508, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-30282398

RESUMO

BACKGROUND: Percutaneous epidural adhesiolysis and neuroplasty (PEAN) has been proven to be safe and effective in treating different spine pathologies, in particular post lumbar surgery syndrome (PLSS). OBJECTIVES: The purpose of this study was to compare the efficacy and complication rates of the 3 different PEAN anatomical approaches (caudal, S1 foraminal, and L5-S1 transforaminal) used to treat PLSS. STUDY DESIGN: This study used a case control, blind study. SETTING: The research took place at the pain clinic and interventional pain practice room at Asyut University Hospital, Assiut, Egypt. METHODS: Sixty consecutive PLSS patients were recruited and randomized into 3 groups (caudal, S1 foraminal, and L5-S1 transforaminal) before receiving adhesiolysis and neuroplasty. All patients underwent nerve conduction studies and magnetic resonance imaging (MRI). Pain severity levels were assessed and measured using the Oswestry Disability Questionnaire (OSW) and the Visual Analog Scale (VAS). Patient satisfaction was evaluated using a Likert scale. The first assessment was performed prior to the procedure to determine the patients' baseline levels of pain severity. Follow-up assessments were performed 1-, 3-, and 6-months after the procedure. RESULTS: Results of the group pairwise analysis indicated that, relative to baseline, there were significant decreases in pain relief scores (VAS and OWS) and functional assessment expressed by patients' satisfaction across all time intervals and in all 3 groups (P < 0.01). Conversely, a between group analysis revealed that VAS, OWS, and patient satisfaction scores were comparable across the 3 groups at all time intervals (P > 0.05). There were no differences in rates of complications between the 3 different groups. LIMITATIONS: Our study was limited by the low number of patients and the short duration (6 months) of follow-up. CONCLUSION: The 3 anatomical approaches (caudal, S1 foraminal, and L5-S1 transforaminal) result in the same outcome with regard to pain relief and complication rate. KEY WORDS: Post lumber surgery syndrome, post laminectomy back pain, percutaneous adhesiolysis, Racz catheter, percutaneous neuroplasty.


Assuntos
Síndrome Pós-Laminectomia/tratamento farmacológico , Hialuronoglucosaminidase/administração & dosagem , Injeções Epidurais/métodos , Manejo da Dor/métodos , Aderências Teciduais/tratamento farmacológico , Estudos de Casos e Controles , Síndrome Pós-Laminectomia/etiologia , Feminino , Humanos , Vértebras Lombares/cirurgia , Região Lombossacral , Masculino , Pessoa de Meia-Idade , Procedimentos Neurocirúrgicos/instrumentação , Procedimentos Neurocirúrgicos/métodos , Dor/etiologia , Dor/cirurgia , Manejo da Dor/instrumentação , Aderências Teciduais/complicações , Resultado do Tratamento , Escala Visual Analógica
18.
Dement Neuropsychol ; 11(2): 206-208, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29213513

RESUMO

Delirium can be conceptualized as an acute decline in cognitive function that typically lasts from hours to a few days. Prolonged delirium can also affect patients with multiple predisposing and/or precipitating factors. In clinical practice, prolonged delirium is often unrecognized, and can be misdiagnosed as other psychiatric disorders. We describe a case of a 59-year-old male presenting with behavioral and cognitive symptoms that was first misdiagnosed as a mood disorder in a general hospital setting. After prolonged delirium due to multiple factors was confirmed, the patient was treated accordingly with symptomatic management. He evolved with progressive improvement of his clinical status. Early diagnosis and management of prolonged delirium are important to improve patient prognosis and avoid iatrogenic measures.


Delirium pode ser conceituado como o declínio agudo na função cognitiva que geralmente dura de horas a dias. O delírio prolongado também pode afetar pacientes com múltiplos fatores predisponentes e/ou precipitantes. Na prática clínica, o delírio prolongado é muitas vezes não reconhecido, e pode ser diagnosticado como outros transtornos psiquiátricos. Aqui, descrevemos o caso de um homem de 59 anos apresentando sintomas comportamentais e cognitivos que foi diagnosticado inicialmente com transtorno de humor em um hospital geral. Após ser diagnosticado delirium prolongado devido a múltiplos fatores, o paciente foi tratado de acordo, evoluindo com melhora progressiva do seu estado clínico. O diagnóstico e o manejo precoces do delirium prolongado são importantes para melhorar o prognóstico do paciente e evitar medidas iatrogênicas.

19.
Curr Neuropharmacol ; 15(5): 789-798, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27928948

RESUMO

BACKGROUND: Akathisia continues to be a significant challenge in current neurological and psychiatric practice. Prompt and accurate detection is often difficult and there is a lack of consensus concerning the neurobiological basis of akathisia. No definitive treatment has been established for akathisia despite numerous preclinical and clinical studies.] Method: We reviewed antipsychotic-induced akathisia including its clinical presentation, proposed underlying pathophysiology, current and under investigation therapeutic strategies. CONCLUSION: Despite the initial promise that second generation antipsychotics would be devoid of akathisia effects, this has not been confirmed. Currently, there are limited therapeutic options for the clinical practice and the evidence supporting the most widely used treatments (beta blockers, anticholinergic drugs) is still absent or inconsistent.


Assuntos
Acatisia Induzida por Medicamentos/etiologia , Antipsicóticos/efeitos adversos , Acatisia Induzida por Medicamentos/classificação , Acatisia Induzida por Medicamentos/diagnóstico , Acatisia Induzida por Medicamentos/epidemiologia , Animais , Bases de Dados Bibliográficas/estatística & dados numéricos , Diagnóstico Diferencial , Humanos , Transtornos Mentais/tratamento farmacológico
20.
Expert Rev Neurother ; 17(9): 883-894, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28750568

RESUMO

INTRODUCTION: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered: The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert commentary: Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.


Assuntos
Adrenérgicos/farmacologia , Antipsicóticos/farmacologia , Antagonistas Colinérgicos/farmacologia , Estimulação Encefálica Profunda/métodos , Agonistas GABAérgicos/farmacologia , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Discinesia Tardia/terapia , Proteínas Vesiculares de Transporte de Monoamina/antagonistas & inibidores , Antipsicóticos/efeitos adversos , Humanos , Discinesia Tardia/tratamento farmacológico , Discinesia Tardia/etiologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa